443797-96-4

Basic information

• Product Name: JNJ-7706621
• Synonyms: 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide JNJ7706621;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide;Aurora Kinase/Cdk Inhibitor
• CAS NO: 443797-96-4
• Molecular Formula: C₁₅H₁₂F₂N₆O₃S
• Molecular Weight: 394.36
• Product Categories: Inhibitors;Inhibitor
• Mol File: 443797-96-4.mol

Chemical Properties

• Melting Point: 149-155℃
• Boiling Point: 676.6 °C at 760 mmHg
• Flash Point: 363 °C
• Appearance: /
• Density: 1.71
• Storage Temp.: +2C to +8C
• Solubility: Soluble in DMSO at 15mg/ml
• PKA: 9.80±0.12(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: JNJ-7706621(CAS DataBase Reference)
• NIST Chemistry Reference: JNJ-7706621(443797-96-4)
• EPA Substance Registry System: JNJ-7706621(443797-96-4)

Safety Data

• Hazardous Substances Data: 443797-96-4(Hazardous Substances Data)

Usage

Uses

Used in Cancer Therapy:
JNJ-7706621 is used as a broad-spectrum inhibitor of cyclin-dependent kinases and aurora kinases, including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A, and Aurora-B. Its ability to induce growth suppression and mitotic defects suggests that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing's sarcoma.

Upstream product

• 443799-31-3 4-((5-amino-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide 
• 18063-02-0 2,6-difluorobenzoylchloride 
• 700805-72-7 phenyl-N'-cyano-N-(4-sulfamoylphenyl)carbamimidate 
• 443799-30-2 4-{3-[(3,5-dimethyl-pyrazol-1-yl)-imino-methyl]-thioureido}-benzenesulfonamide 
• 51908-29-3 4-isothiocyanatobenzene sulfonamide 
• 63-74-1 sulfanilamide 
• 172935-91-0 2,6-difluorobenzoic hydrazide 
• 700805-72-7 N-[4-(aminosulfonyl)phenyl]-N'-cyanocarbamidic acid phenyl ester 
• 79463-77-7 N-cyanodiphenylcarbonimidate 

Downstream Products

• 863030-90-4 HBr salt of 4-[5-Amino-1-(2,6-difluoro-benzoyl)-1H-[1,2,4]triazol-3-ylamino]-benzenesulfonamide 
• 863030-89-1 HCl salt of 4-[5-Amino-1-(2,6-difluoro-benzoyl)-1H-[1,2,4]triazol-3-ylamino]-benzenesulfonamide 

Relevant articles and documents

Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3

Tyrosine kinase 2 (TYK2) is required for signaling of interleukin-23 (IL-23), which plays a key role in rheumatoid arthritis. Presented is the design and synthesis of 1,2,4-triazoles, and the evaluation of their inhibitory activity against the Janus associated kinases TYK2 and JAKs 1-3.

1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: Synthesis and evaluation of biological activities

A series of 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues were synthesized as cyclin-dependent kinase (CDK) inhibitors. These compounds showed potent and selective CDK1 and CDK2 inhibitory activities and inhibited in vitro cellular proliferation in various human tumor cells. Representative compound 3b demonstrated in vivo efficacy in a human melanoma A375 xenograft model in nude mice.

PROCESS FOR THE PREPARATION OF SUBSTITUTED TRIAZOLE COMPOUNDS

The present invention is directed to a novel process for the preparation of substituted triazole compounds, useful in the treating or ameliorating a selective kinase or dual-kinase mediated disorder. The process of the present invention preferentially pro

Substituted triazole diamine derivatives as kinase inhibitors

The present invention provides substituted triazole diamine derivatives as selective kinase or dual-kinase inhibitors and a method for treating or ameliorating a selective kinase or dual-kinase mediated disorder.